Business Wire

Mobile Industry Backs GSMA Embedded SIM Specification to Benefit from US$1.1 Trillion Internet of Things Opportunity

Del

The GSMA today announced that Indosat, Tele2 and Telefónica | Vivo are the latest mobile operators to launch commercial solutions based on the GSMA Embedded SIM Specification for the remote over-the-air provisioning of machine-to-machine (M2M) devices such as smart meters or connected cars. The Embedded SIM Specification is now backed by 23 mobile operators, including members of the Global M2M Association (GMA) and the M2M World Alliance, and 11 operators worldwide have launched commercial solutions.¹ The adoption of a single, common and interoperable specification will reduce fragmentation and help the industry to take advantage of the fast-growing Internet of Things market, estimated to be worth US$1.1 trillion by 2020².

“It is clear that the industry is united behind this global standard which allows mobile operators to provide scalable, reliable and secure connectivity for a range of diverse services such as smart meters, traffic lights and home security, among many others,” said Alex Sinclair, Acting Director General and Chief Technology Officer, GSMA. “With commercial solutions already available today, we encourage additional operators and ecosystem players to adopt the specification in order to capitalise on the tremendous market opportunity enabled by the IoT.”

GSMA Intelligence research highlights that nearly 75 per cent³ of global M2M connections are now serviced by mobile operators that are deploying or are committed to the GSMA solution, underscoring the momentum behind the specification. Analyst firm Machina Research has also published research confirming that embedded SIM connections will account for 25 per cent of the embedded share of gross cellular additions by 2020 4 .

Profile Interoperability and Updated Test Specifications

The latest release of the GSMA Embedded SIM Specification includes a feature called ‘Profile Interoperability ’, which enables an operator to create a SIM Profile which can then be downloaded to any compliant eUICC regardless of the manufacturer. This feature will allow operators to easily connect a greater number of M2M devices, opening up the market, reducing fragmentation and providing additional commercial flexibility for original equipment manufacturers and M2M service providers. The GSMA has also released new test specifications to give assurance that products have the correct security levels and are compliant with the GSMA Embedded SIM Specification.

GSMA Embedded SIM at Mobile 360 Series Conferences

The GSMA’s Connected Living Programme will participate at the GSMA Mobile 360 Series of events taking place in Cape Town, Dubai, Atlanta and Brussels in the fourth quarter of 2015. Through workshops, panel discussions and keynote presentations, the Connected Living team will discuss the adoption of the GSMA Embedded SIM Specification, as well as the deployment of low power, wide area networks and the development of IoT network security. For further information on the Mobile 360 Series, visit www.mobile360series.com/.

For more information on the GSMA’s Embedded SIM please go to: http://www.gsma.com/connectedliving/connected-living-mobilising-the-internet-of-things/.

-ENDS-

Notes to Editors

1. Operators who have launched commercial solutions are: AT&T, Bell Canada, Etisalat, Indosat, NTT Docomo, Orange, Tele2, Telefonica | Vivo, Telefonica Group, Teliasonera and Vodafone

2. Machina Research (https://machinaresearch.com/)

3. According to GSMA Intelligence, as of Q2 2015, there are 273 million cellular M2M connections for all operators committed to launching the GSMA Embedded SIM Specification accounting for 75% of total global cellular M2M connections.

4. Machina Research (https://machinaresearch.com/)

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with more than 250 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai and the Mobile 360 Series conferences.

For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.

Contact information

Media:
For the GSMA
Charlie Meredith-Hardy
+44 7917 298428
CMeredith-Hardy@webershandwick.com
GSMA Press Office
pressoffice@gsma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease18.7.2018 21:45Pressemelding

VIEW E-MEDIA KIT – Emmaus Life Sciences, Inc. (Emmaus) announced today that the New England Journal of Medicine (NEJM) has published the results of its 48-week phase 3 clinical trial of Endari™ (L-glutamine oral powder) which supported the FDA approval in July 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. The article reports results that showed significantly fewer sickle cell crises in those receiving Endari compared to placebo by 25 percent; p=0.005 (median 3 vs. median 4) and significantly fewer hospitalizations by 33 percent; p=0.005 (median 2 vs. median 3). Additional findings showed lower cumulative days in hospital of 41 percent; p=0.02 (median 6.5 days vs. median 11 days) and a lower incidence of acute chest syndrome (ACS) by more than 60 percent; p=0.003 (13 of 152 patients [8.6%] had at least 1 ACS compared with 18 of 78 in the placebo group [23.1%]). The most common adverse reactions, occurring in great

Tigo Releases State-of-the-art Wireless Technology – Mesh – as the New Solar Communication Architecture for the TS4 Platform18.7.2018 19:41Pressemelding

Tigo®, pioneer of the smart modular Flex MLPE platform, today announced the release of its new Mesh communication architecture. This state-of-the-art wireless technology directly translates to customer benefits – including simplifying the solar design process and accelerating the commissioning steps. The complete Tigo solution uses a simple yet powerful data collection technology that covers the widest ranges of residential & commercial installations at the lowest cost. With Mesh and the recently announced Tigo Access Point (TAP), customers eliminate the need to address any roof obstruction or orientation constraint. To learn more about Mesh and TAP, register for Tigo’s free, online webinar “The Future of Solar is Wireless” on Wednesday July 25th, 2018 at 10am PDT. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180718005827/en/ Mesh is Tigo's proprietary software that allows each TS4 unit to act as a repeater, extending the

ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 201818.7.2018 17:21Pressemelding

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, in Amsterdam, The Netherlands. The data being presented this year has a strong focus on novel exploratory therapeutic options and innovative treatment strategies, as well as improving awareness and understanding of key issues that continue to affect the HIV community. John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare, commented, “As we see advancements in the treatment options available to people living with HIV, our research efforts over the past few years have been focused on moving beyond viral load and addressing some of the unresolved issues that people living with HIV face, such as the potential long-term risks and toxicities that can be associated with li

Xilam: H1 2018 Revenue: +50%18.7.2018 16:00Pressemelding

Regulatory News: The Xilam Group (Paris:XIL) posted consolidated H1 2018 revenue of EUR 13,866 thousand, an increase of 50%. This increase represents an excellent performance, as it follows on the heels of growth of 54% in H1 2017. Revenue for the first part of this financial year breaks down as follows. In thousands of euros 30.06.2018 (1) 30.06.2017 Change New productions 8,465 4,571 +85% Catalogue 5,385 4,652 +16% Other 16 16 +0% Revenue and subsidies 13,866 9,239 +50% (1) Unaudited data. Remarkable success for new releases +85% Excellent H1 growth was driven by the two main businesses, New Productions and Catalogue. In New Productions, H1 deliveries generated record revenue of EUR 8,465 thousand, an 85% increase compared with H1 2017, and confirmed Xilam’s position as a major European animation company. Catalogue revenue was up 16% compared with H1 2017, thanks again to traditional TV channels and digital platforms, in both France and abroad. A fast-paced delivery schedule Thanks t

Department for International Trade: Life Sciences at the Heart of UK Economy18.7.2018 12:38Pressemelding

The Government will today (Wednesday 18 July) host the second in a series of roundtables with stakeholders from key life science businesses, demonstrating the importance of the sector to the UK economy. The Chancellor, International Trade Secretary, Business Secretary and Health and Social Care Secretary will be amongst those that meet with senior representatives from leading UK and international life sciences companies as the UK positions itself as the global home of health innovation, welcoming overseas investment and seeking to boost exports in the process. Discussions at the roundtable will focus on how the future of the Life Sciences sector will be supported by the delivery of our modern Industrial Strategy, ensuring that the UK is ‘open for business’ with a positive business environment, our ambitions for a comprehensive agreement with the EU on our future relationship and the development and implementation of our independent trade policy. To date, the government has engaged sign

Universal Laser Systems Expands Its Materials Database with 3M, Victrex and Dexmet Materials18.7.2018 12:05Pressemelding

Universal Laser Systems (ULS) announces the addition of 3M™, Victrex® and Dexmet materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The 3M, Victrex and Dexmet materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: 3M™ Extreme Sealing Tape 4412N 3M™ Thermally Conductive Silicone Interface Pad 5516 Victrex® APTIV® PEEK Film Dexmet PolyGrid® 8PTFE10-125ST Expanded PTFE Dexmet MicroGrid® AL 25 Expanded Aluminum Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advantages of deploying laser technology within their manufacturing, research and d